Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VYGR Stock Forecast 2025-2026
$4.28
Current Price
$237.97M
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VYGR Price Targets
+484.1%
To High Target of $25.00
+180.4%
To Median Target of $12.00
+86.9%
To Low Target of $8.00
VYGR Price Momentum
+4.6%
1 Week Change
+1.2%
1 Month Change
-33.6%
1 Year Change
-24.5%
Year-to-Date Change
-36.0%
From 52W High of $6.69
+61.5%
From 52W Low of $2.65
📊 TOP ANALYST CALLS
Did VYGR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Voyager is one of their latest high-conviction picks.
Latest VYGR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, VYGR has a bullish consensus with a median price target of $12.00 (ranging from $8.00 to $25.00). The overall analyst rating is N/A (N/A/10). Currently trading at $4.28, the median forecast implies a 180.4% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 484.1% upside. Conversely, the most conservative target is provided by Yun Zhong at Wedbush, suggesting a 86.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VYGR Analyst Ratings
12
Buy
0
Hold
0
Sell
VYGR Price Target Range
Low
$8.00
Average
$12.00
High
$25.00
Current: $4.28
Latest VYGR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VYGR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $25.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $30.00 |
| Aug 7, 2025 | Wedbush | Yun Zhong | Outperform | Maintains | $8.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Mar 13, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $12.00 |
| Mar 12, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $10.00 |
| Mar 12, 2025 | Wedbush | Yun Zhong | Outperform | Reiterates | $N/A |
| Mar 12, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $N/A |
| Mar 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Jan 10, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Initiates | $5.73 |
| Dec 2, 2024 | Citigroup | Samantha Semenkow | Buy | Initiates | $12.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $14.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Oct 16, 2024 | Leerink Partners | Lili Nsongo | Outperform | Initiates | $15.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Aug 7, 2024 | Wedbush | Laura Chico | Neutral | Maintains | $7.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
Voyager Therapeutics Inc. (VYGR) Competitors
The following stocks are similar to Voyager based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Voyager Therapeutics Inc. (VYGR) Financial Data
Voyager Therapeutics Inc. has a market capitalization of $237.97M with a P/E ratio of 6.1x. The company generates $31.32M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -45.7% quarter-over-quarter, while maintaining an operating margin of -228.9% and return on equity of -46.1%.
Valuation Metrics
Market Cap
$237.97M
Enterprise Value
$67.41M
P/E Ratio
6.1x
PEG Ratio
0.0x
Price/Sales
7.6x
Growth & Margins
Revenue Growth (YoY)
-45.7%
Gross Margin
N/A
Operating Margin
-228.9%
Net Margin
0.0%
EPS Growth
-45.7%
Financial Health
Cash/Price Ratio
+87.8%
Current Ratio
6.2x
Debt/Equity
17.5x
ROE
-46.1%
ROA
-24.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Voyager Therapeutics Inc. (VYGR) Business Model
About Voyager Therapeutics Inc.
What They Do
Develops gene therapies for neurological diseases.
Business Model
The company operates by developing gene therapies targeting severe neurological diseases, leveraging proprietary AAV capsid engineering and delivery technology to enhance the efficacy of therapeutic gene expression. Voyager Therapeutics generates revenue through collaborations with pharmaceutical companies, which may include milestone payments and royalties upon successful commercialization of its therapies.
Additional Information
Headquartered in Cambridge, Massachusetts, Voyager Therapeutics is positioned as a key innovator in biotechnology and precision medicine. Its focus on conditions with limited treatment options such as Parkinson’s and Huntington’s diseases highlights its commitment to addressing unmet medical needs in the neurology space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
172
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Country
United States
IPO Year
2015
Website
www.voyagertherapeutics.comVoyager Therapeutics Inc. (VYGR) Latest News & Analysis
Latest News
Quick Summary
Voyager Therapeutics reported a Q3 2025 cash position of $229M, ensuring funding through 2028. Upcoming clinical data for VY7523 and VY1706 expected in 2026, alongside a new discovery program.
Why It Matters
Voyager Therapeutics shows strong cash reserves and a promising pipeline, including upcoming clinical data and collaborations, which may enhance growth prospects and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Voyager Therapeutics (VYGR) reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of $0.53, but worse than a $0.16 loss per share a year earlier.
Why It Matters
Voyager Therapeutics' smaller-than-expected quarterly loss signals potential operational improvement, which may boost investor confidence and affect stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Transition Bio and Voyager Therapeutics have formed a collaboration to develop small molecules targeting TDP-43 pathology in ALS and FTD, addressing significant neurodegenerative diseases.
Why It Matters
The collaboration between Transition Bio and Voyager Therapeutics could lead to breakthroughs in treating ALS and FTD, potentially boosting stock performance and market interest in both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Voyager Therapeutics (VYGR) saw significant trading volume recently, but upcoming earnings estimate revisions may hinder further stock price increases.
Why It Matters
Increased trading volume suggests heightened investor interest, but negative earnings estimate revisions may signal potential declines, affecting VYGR's short-term performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript
3 months ago
Quick Summary
Voyager Therapeutics will participate in Citi's Biopharma Back to School Conference on September 2, 2025, with key executives including the CEO and CFO present.
Why It Matters
The participation of Voyager Therapeutics at a prominent biotech conference signals potential updates on their pipeline and financial health, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Voyager to Present at Upcoming Investor Conferences
3 months ago
Quick Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will participate in upcoming investor conferences, focusing on genetics-based treatments for neurological diseases.
Why It Matters
Voyager Therapeutics' participation in investor conferences signals potential growth opportunities and increased visibility, which may attract investor interest and affect stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VYGR Stock
What is Voyager Therapeutics Inc.'s (VYGR) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Voyager Therapeutics Inc. (VYGR) has a median price target of $12.00. The highest price target is $25.00 and the lowest is $8.00.
Is VYGR stock a good investment in 2026?
According to current analyst ratings, VYGR has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VYGR stock?
Wall Street analysts predict VYGR stock could reach $12.00 in the next 12 months. This represents a 180.4% increase from the current price of $4.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Voyager Therapeutics Inc.'s business model?
The company operates by developing gene therapies targeting severe neurological diseases, leveraging proprietary AAV capsid engineering and delivery technology to enhance the efficacy of therapeutic gene expression. Voyager Therapeutics generates revenue through collaborations with pharmaceutical companies, which may include milestone payments and royalties upon successful commercialization of its therapies.
What is the highest forecasted price for VYGR Voyager Therapeutics Inc.?
The highest price target for VYGR is $25.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 484.1% increase from the current price of $4.28.
What is the lowest forecasted price for VYGR Voyager Therapeutics Inc.?
The lowest price target for VYGR is $8.00 from Yun Zhong at Wedbush, which represents a 86.9% increase from the current price of $4.28.
What is the overall VYGR consensus from analysts for Voyager Therapeutics Inc.?
The overall analyst consensus for VYGR is bullish. Out of 20 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are VYGR stock price projections?
Stock price projections, including those for Voyager Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:44 AM UTC